Per the FDA meeting notice, the agency reviewed each peptide for a narrow use: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, and MOTS-c for obesity and osteoporosis
Medications like orforglipron (an oral, non-peptide GLP-1 agonist), survodutide (a dual glucagon/GLP-1 agonist), and CagriSema (combining cagrilintide with semaglutide) are advancing through clinical trials
GIP receptor activation enhances insulin sensitivity at the cellular level
As a dietitian, I rarely recommend blanket supplements (i.e., everyone needs this!), but for the GLP-1 community, since their intake is decreased significantly, there are a few I do recommend, says Reisdorf